If you have protein in the urine and African descent, Hispanic or American Indian you might have a gene call APOL1 contributing kidney disease. This study will test if you have change in the gene. If you do have that change you can participate in this study .

Do you have lupus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM)? You may be eligible for a new CAR-T therapy conducted at University of North Carolina at Chapel Hill. Please reach out to learn more about this new innovative treatment.

This research is being done in participants who have Hepatocellular Carcinoma (HCC), also referred to as Liver Cancer, to evaluate how 3 drugs work in combination, and which dose is the best to treat your disease. The 3 drugs are casdozokitug (casdozo-key-tug), toripalimab (tor-i-pal-i- mab) and bevacizumab (bev-uh-siz-oo-mab). Toripalimab and bevacizumab have been approved by the Food and Drug Administration (FDA) to treat other cancers, but not Liver cancer. Casdozokitug has not been approved by the FDA to treat any cancers.

If you have metabolic liver disease (MASLD) or its more severe form, MASH, you may be eligible to join a research study testing a new oral drug as a treatment option. This study is evaluating an investigational drug called denifanstat, which may help reduce liver fat and prevent further liver damage. By joining, you'll receive close monitoring of your liver health at no cost, and you could help advance treatment options for others with liver disease. Participation is voluntary, and you'll be able to continue your regular medical care throughout the study. If you're interested in new treatment possibilities and improving your liver health, this could be the right opportunity for you. Speak with our study team today to learn more and see if you qualify!

We are studying an investigational drug, denifanstat, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with noncirrhotic NASH (non-alcoholic steatohepatitis) MASH (metabolic dysfunction-associated steatohepatitis).

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with Compensated Cirrhosis due to NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

The purpose of this study is to find out whether the addition of HDV to Humalog® will improve diabetes control by reducing high blood sugar after meals and/or reducing the risk of low blood sugar (hypoglycemia) during insulin treatment. The safety and tolerability of Humalog® with or without added HDV will also be evaluated. The study drugs will be administered by subcutaneous (under the skin) injection.

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

This study aims to investigate the effectiveness and safety of retatrutide, a new diabetes medication) at doses of 4 mg, 9 mg, or 12 mg that will be taken as a weekly injection for about 1 year, compared to a placebo. A participant's change in HbA1c level will be primary outcome of interest. We are seeking participants with type 2 diabetes that has affected kidney function and are currently taking long-acting insulin with metformin and/or a SGLT2 inhibitor.